1,2,3,4-tetrahydroisoquinolin-6-ylmethanol hydrochloride | 2152637-00-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 四氢异喹啉
• 英文名称: 1,2,3,4-tetrahydroisoquinolin-6-ylmethanol hydrochloride
• 英文别名: (1,2,3,4-Tetrahydroisoquinolin-6-yl)methanol hydrochloride；1,2,3,4-tetrahydroisoquinolin-6-ylmethanol;hydrochloride
• CAS: 2152637-00-6
• 化学式: C₁₀H₁₃NO*ClH
• 分子量: 199.68
• InChiKey: UYVBFIYDZJEHAL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.25
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  32.3
• 氢给体数：
  3
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  6-(羟基甲基)-3,4-二氢异喹啉-2(1H)-羧酸叔丁酯 在 盐酸 作用下， 以 甲醇 为溶剂， 反应 16.0h， 以99%的产率得到1,2,3,4-tetrahydroisoquinolin-6-ylmethanol hydrochloride
  参考文献：
  名称：

  WO2009/1128

  摘要：

  公开号：

文献信息

• Cyclopropyl-amide compounds as dual LSD1/HDAC inhibitors
  申请人：Jubilant Epicore LLC

  公开号：US11352322B2

  公开（公告）日：2022-06-07

  The present disclosure describes novel compounds of the general Formula (I), their analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts, pharmaceutical compositions, metabolites, and prodrugs thereof. These compounds can inhibit both LSD and HDAC and are useful as therpeautic or ameliorating agent for diseases that are involved in cellular growth such as malignant tumors, schizophrenia, Alzheimer's disease, parkinson's disease and the like.

  本公开描述了通式（I）的新型化合物及其类似物、同分异构体、立体异构体、多晶型、水合物、溶液、药学上可接受的盐、药物组合物、代谢物和原药。这些化合物可同时抑制 LSD 和 HDAC，可用作治疗或改善涉及细胞生长的疾病的药物，如恶性肿瘤、精神分裂症、阿尔茨海默病、帕金森病等。
• CYCLOPROPYL-AMIDE COMPOUNDS AS DUAL LSD1/HDAC INHIBITORS
  申请人：Jubilant Epicore LLC

  公开号：US20200308110A1

  公开（公告）日：2020-10-01

  The present disclosure describes novel compounds of the general Formula (I), their analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts, pharmaceutical compositions, metabolites, and prodrugs thereof. These compounds can inhibit both LSD and HDAC and are useful as therpeautic or ameliorating agent for diseases that are involved in cellular growth such as malignant tumors, schizophrenia, Alzheimer's disease, parkinson's disease and the like.
• [EN] 1,2-CYCL0HEXANE DICARBOXAMIDES AS CATHEPSIN INHIBITORS<br/>[FR] 1,2-CYCLOHEXANE DICARBOXAMIDES UTILISÉS COMME INHIBITEURS DES CATHEPSINES
  申请人：ASTRAZENECA AB

  公开号：WO2009001128A1

  公开（公告）日：2008-12-31

  [EN] The present invention relates to compounds and compositions for treating diseases associated with cysteine protease activity. The compounds are reversible inhibitors of cysteine proteases, including cathepsins B, K, C, F, H, L, O, S, W and X. Of particular interest are diseases associated with Cathepsin K.
  [FR] L'invention concerne des composés et des compositions destinés au traitement de maladies associées à l'activité cystéine protéase. Les composés de l'invention sont des inhibiteurs réversibles des cystéine protéases, entre autres les cathepsines B, K, C, F, H, L, O, S, W et X. L'invention offre un intérêt particulier pour les maladies associées à la cathepsine K. Formule (I):